- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787251
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
Randomized, Open, Positive Drug Control, Multicenter Clinical Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Squamous Cell Carcinoma With Chemotherapy in Patients Treated With Apatinib Mesylate
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathological/histological diagnosis of esophageal squamous cell carcinoma; and at least one measurable lesion according to RECIST criteria (version 1.1);
- Patients who have undergone radical resection of esophageal cancer and who have failed after first-line systemic chemotherapy (which may include platinum, taxane or fluorouracil) after recurrence (recurrence of postoperative adjuvant chemotherapy within 6 months) Considered as first-line treatment, and the same progress in the field of radiation can be seen as recurrence;
- Age: 18-75 years old; both men and women;
- ECOG PS Rating: 0-1 points;
- Estimated survival period ≥ 3 months;
- ≥ 4 weeks from the last cytotoxic drug;
The main organs function normally, that is, meet the following criteria:
Blood routine examination:
- HB≥90 g/L; (no blood transfusion within 14 days)
- ANC ≥ 1.5 × 109 / L;
- PLT ≥ 80 × 109 / L;
Biochemical examinations must meet the following criteria:
- ALT and AST < 2.5 ULN; if there is liver metastasis, ALT and AST < 5 ULN;
- TBIL ≤ 1.5ULN;
- Plasma Cr≤1.5ULN or creatinine clearance (CCr)≥60ml/min
- Subjects volunteered to participate in the study, signed informed consent, and were well-adhered to follow-up.
- Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months of the end of the study; negative serum or urine pregnancy tests within seven days prior to study enrollment And must be non-lactating patients; males should agree to patients who must use contraception during the study period and within 6 months after the end of the study period.
Exclusion Criteria:
- Those who have used anti-tumor angiogenesis drugs to treat failure;
- Patients with residual esophagus, residual stomach or anastomotic recurrence;
- Unable to swallow, chronic diarrhea and intestinal obstruction, which obviously affect the taking and absorption of drugs;
- Patients with brain metastases with symptoms or symptoms controlled for less than 3 months;
- Long-term unhealed wounds and fractures;
- Have clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood above ++), history of gastrointestinal bleeding within 6 months; coagulation abnormalities (PT>16 s, APTT>43 s, TT>21 s, Fbg< 2 g/L), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy;
- Overactive/venous thrombosis occurred within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism;
- Imaging shows that the tumor has invaded the important perivascular circumference or that the patient is likely to invade the important blood vessels during the follow-up study and cause fatal bleeding.
- Persons with a history of psychotropic substance abuse who are unable to resolve or have a mental disorder;
- Participated in other clinical trials of anti-tumor drugs within four weeks;
- Have a history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation;
- According to the investigator's judgment, there are serious concomitant illnesses that compromise the safety of the patient or affect the patient's completion of the study.
Patients with any severe and/or uncontrolled diseases, including:
- Blood pressure control is unreasonable (retraction pressure >150mmHg, diastolic pressure >100mmHg) Patients: I have myocardial ischemia or myocardial infarction above grade I, arrhythmia (including QT interval >440ms) and grade I cardiac insufficiency;
- Active or uncontrolled serious infections;
- Liver diseases such as cirrhosis, decompensated liver disease, chronic active hepatitis;
- Poor diabetes control (fasting blood glucose FBG>10mmol/L);
- Urine routine indicates urinary protein >++, and confirmed 24-hour urine protein quantitation >1.0g.
- The investigator believes that it is not suitable for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: experimental group
It is recommended that the initial dose of apatinib is 500mg po qd.
Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks.
If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
|
It is recommended that the initial dose of apatinib is 500mg po qd.
Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks.
If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
|
Active Comparator: Control group
The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected). The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient. In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice. |
The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient. In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: One year from admission
|
progression-free survival
|
One year from admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: One year from admission
|
Overall Survival
|
One year from admission
|
DCR
Time Frame: One year from admission
|
disease control rate
|
One year from admission
|
ORR
Time Frame: One year from admission
|
Objective Response Rate
|
One year from admission
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Recurrence
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- Nanjing Drum Tower Hospital
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
University of Michigan Rogel Cancer CenterGenentech, Inc.TerminatedLoco-regional Esophageal Cancer
-
Universitaire Ziekenhuizen KU LeuvenCompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)Belgium
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & Institute; Tianjin Medical University Cancer... and other collaboratorsRecruitingEsophageal Neoplasm Metastatic | Esophageal Cancer Stage IVbChina
-
Emory UniversityNovartisCompletedEsophageal Cancer | Neoplasms, EsophagealUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)RecruitingNeoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)United States
-
CellSeed Inc.Terminated
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
Clinical Trials on Apatinib
-
Elevar TherapeuticsTerminatedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Peking University Cancer Hospital & InstituteRecruiting
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Tianjin Medical University Cancer Institute and...Unknown
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting